Barely Significant
← all excerpts

Ocrelizumab: a new milestone in multiple sclerosis therapy.

Ther Adv Neurol Disord · 2018 · PMC5952271 · PMID 29774057

Europe PMCDOI
1
hedged sentence
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

highly significantp < 0.0001actually significant
A total of 220 patients completed this 24-week study, and highly significant differences in the total number of gadolinium-enhanced T1 lesions were observed in both ocrelizumab groups ( p < 0.0001) at weeks 12, 16, 20 and 24 when compared with the placebo group.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.